Skip to main content
SpringerLink
Log in

Botulinum Toxin for Migraine

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Botulinum Toxins, Fillers and Related Substances

  • 242 Accesses

Abstract

The use of onabotulinumtoxinA in headaches starts in 1997 with exploratory studies for migraine and other headache subtypes. At the same time, laboratory research explored the nonmotor effects of onabotulinumtoxinA.

However, the efficacy was demonstrated just for chronic migraine (CM) and the use was approved in 2010 based on two studies, PREEMPT 1 and 2. These studies consisted of a 24-week randomized, double-blind, placebo-controlled phase followed by a 32-week onabotulinumtoxinA open-label phase. Study injections were given at 31 fixed and 8 optional sites with 5U in each site (total 155U to 195U, mean 165U) across seven head and neck muscle areas (procerus, corrugator, frontalis, temporalis, occipitalis, cervical paraspinal, and trapezius), each 12 weeks.

OnabotulinumtoxinA has shown a safe and effective prophylactic treatment option for patients with CM. Accurate target muscle localization and injection angles and depths are required to achieve optimal outcomes and to minimize adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.

    Article  CAS  Google Scholar 

  • Binder WJ, Blitzer A, Brin MF. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg. 1998a;24:1198–205.

    CAS  PubMed  Google Scholar 

  • Binder WJ, et al. Botulinum toxin type A (BTX-A) for migraine: an open label assessment. Mov Disord. 1998b;13:241. (Abstract)

    Google Scholar 

  • Binder WJ, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123:669–76.

    Article  CAS  Google Scholar 

  • Blumenfeld A, Bloudek L, Becker W, Buse D, Varon S, Maglinte G. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–55.

    Article  Google Scholar 

  • Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57:766–77.

    Article  Google Scholar 

  • Brin MF, Blitzer A. History of onabotulinumtoxinA therapeutic. In: Carruthers A, Carruthers J, editors. Botulinum toxin. London: Saunders Elsevier; 2013. p. 6–12.

    Google Scholar 

  • Diener HC, Bussone G, Van Oene JC, TOPMAT-MIG-201(TOP-CHROME) Study Group, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23. Erratum in: Cephalalgia 2007; 27(8):962.

    Article  Google Scholar 

  • Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.

    Article  CAS  Google Scholar 

  • Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53:1850–3.

    Article  CAS  Google Scholar 

  • Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

    Article  Google Scholar 

  • Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–82.

    Article  CAS  Google Scholar 

  • Lamanna C, McElroy OE, Eklund HW. The purification and crystallization of Clostridium botulinum type A toxin. Science. 1946;103:613–4.

    Article  CAS  Google Scholar 

  • Lawrence GW, Dolly JO. Multiple forms of SNARE complexes in exocytosis from chromaffin cells: effects of Ca (2+), MgATP and botulinum toxin type A. J Cell Sci. 2002;115:667–73.

    CAS  PubMed  Google Scholar 

  • Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–22. quiz 123–126

    Article  Google Scholar 

  • Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.

    Article  CAS  Google Scholar 

  • Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885–94.

    Article  CAS  Google Scholar 

  • Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112:463–6.

    Article  Google Scholar 

  • Mathew NT, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307.

    Article  Google Scholar 

  • Riesco N, Cernuda-Morollon E, Martınez-Camblor P, Perez-Alvarez AI, Verano L, Garcıa-Cabo C, Serrano-Pertierra E, Pascual J. Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: a study in chronic migraine patients. Cephalalgia. 2017;37(9):823–7.

    Article  CAS  Google Scholar 

  • Scott AB. Botulinum toxin injection in to extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17:21–5.

    CAS  PubMed  Google Scholar 

  • Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia. 2010;30:207–13.

    Article  CAS  Google Scholar 

  • Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115–23.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurological Clinic Maria Eduarda Nobre, Rio de Janeiro, Brazil

    Maria Eduarda Nobre

  2. Faculdade de Medicina Barão de Mauá, Ribeirão Preto, São Paulo, Brazil

    Marcelo Cedrinho Ciciarelli

  3. Universidade Federal Fluminense, Niterói, Brazil

    Jano Alves Souza

Authors
  1. Maria Eduarda Nobre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcelo Cedrinho Ciciarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jano Alves Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jano Alves Souza .

Editor information

Editors and Affiliations

  1. Universidade Federal Fluminense, Niterói, São Paulo, Brazil

    Maria Claudia Almeida Issa

  2. Lexbios Medica S/S, São Paulo, São Paulo, Brazil

    Bhertha Tamura

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nobre, M.E., Ciciarelli, M.C., Souza, J.A. (2019). Botulinum Toxin for Migraine. In: Issa, M., Tamura, B. (eds) Botulinum Toxins, Fillers and Related Substances. Clinical Approaches and Procedures in Cosmetic Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-20253-2_42-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20253-2_42-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20253-2

  • Online ISBN: 978-3-319-20253-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Botulinum Toxin for Migraine
    Published:
    02 January 2019

    DOI: https://doi.org/10.1007/978-3-319-20253-2_42-2

  2. Original

    Botulinum Toxin for Migraine
    Published:
    28 March 2018

    DOI: https://doi.org/10.1007/978-3-319-20253-2_42-1

Search

Navigation